Cover Image
市場調查報告書

CymaBay Therapeutics, Inc.:產品平台分析

CymaBay Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 333713
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
CymaBay Therapeutics, Inc.:產品平台分析 CymaBay Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 29 Pages
簡介

本報告提供CymaBay Therapeutics, Inc.的醫藥品的研究開發 (R&D) 趨勢相關分析、開發活動的整體進展,及各開發階段 (相/階段) 的開發中產品資訊、各標的、作用機制 (MoA)、給藥途徑 (RoA)、分子類型的詳細趨勢、近來主要的動向 (新聞稿等)、最後階段/中斷計劃的概要等資訊彙整,為您概述為以下內容。

目錄

  • CymaBay Therapeutics, Inc.:最新趨勢
    • 概要
    • 主要資訊
    • 主要資料
  • CymaBay Therapeutics, Inc.:研究開發 (R&D) 概要
    • 主要的治療領域
  • CymaBay Therapeutics, Inc.:開發平台分析
    • 開發中產品:各開發階段
    • 開發中產品:單劑療法
    • 開發中產品:轉出授權產品
      • 轉出授權產品/聯合治療的模式
  • CymaBay Therapeutics, Inc.:開發中產品的概要
    • 各臨床實驗階段的開發中產品
      • 第二階段產品/聯合治療的模式
      • 第一階段產品/聯合治療的模式
  • CymaBay Therapeutics, Inc.:藥物簡介
    • arhalofenate
      • 產品概要
      • 作用機制
      • 研究開發 (R&D) 的發展
    • MBX-2982
    • MBX-8025
  • CymaBay Therapeutics, Inc.:開發平台分析
    • 開發中產品:各標的
    • 開發中產品:各給藥途徑
    • 開發中產品:各分子類型
    • 開發中產品:各作用機制
  • CymaBay Therapeutics, Inc.:開發中產品的最新趨勢
  • CymaBay Therapeutics, Inc.:暫停的計劃
  • CymaBay Therapeutics, Inc.:產業據點、相關企業
    • 總公司
  • 附錄

圖表一覽

目錄
Product Code: GMDHC07137CDB

Summary

Global Markets Direct's, 'CymaBay Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the CymaBay Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CymaBay Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CymaBay Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CymaBay Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CymaBay Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate CymaBay Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CymaBay Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CymaBay Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CymaBay Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CymaBay Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CymaBay Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CymaBay Therapeutics, Inc. Snapshot
    • CymaBay Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • CymaBay Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • CymaBay Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • CymaBay Therapeutics, Inc. - Pipeline Products Glance
    • CymaBay Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • CymaBay Therapeutics, Inc. - Drug Profiles
    • arhalofenate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-2982
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-8025
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CymaBay Therapeutics, Inc. - Pipeline Analysis
    • CymaBay Therapeutics, Inc. - Pipeline Products by Target
    • CymaBay Therapeutics, Inc. - Pipeline Products by Route of Administration
    • CymaBay Therapeutics, Inc. - Pipeline Products by Molecule Type
    • CymaBay Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • CymaBay Therapeutics, Inc. - Recent Pipeline Updates
  • CymaBay Therapeutics, Inc. - Dormant Projects
  • CymaBay Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CymaBay Therapeutics, Inc., Key Information
  • CymaBay Therapeutics, Inc., Key Facts
  • CymaBay Therapeutics, Inc. - Pipeline by Indication, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • CymaBay Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • CymaBay Therapeutics, Inc. - Out-Licensed Products in Pipeline, 2015
  • CymaBay Therapeutics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • CymaBay Therapeutics, Inc. - Phase II, 2015
  • CymaBay Therapeutics, Inc. - Phase I, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Target, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • CymaBay Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • CymaBay Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • CymaBay Therapeutics, Inc. - Dormant Developmental Projects,2015

List of Figures

  • CymaBay Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • CymaBay Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • CymaBay Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • CymaBay Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top